Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma

Joon Ho Moon, Bo Hee Lee, Jeong A. Kim, Yoo Jin Lee, Yee Soo Chae, Ho Young Yhim, Jae Yong Kwak, Young Rok Do, Yong Park, Moo Kon Song, Ho Jin Shin, Therasa Kim, Je jung Lee, Deok Hwan Yang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study retrospectively investigated the optimal timing of radiotherapy (RT) in patients with limited-stage extranodal NK/T-cell lymphoma (ENTKL). Among 158 patients with newly diagnosed stage I/II ENKTL, 61 patients were treated with sequential chemotherapy followed by radiotherapy (SCRT), 55 with concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy (CCRT/CT), and 42 with chemotherapy (CT) only. The 5-year overall survival (OS) rate did not differ between SCRT (77.7 ± 5.5%) and CCRT/CT (68.9 ± 6.8%; p = 0.234). In the SCRT group, 18 patients (29.5%) relapsed within the RT field and 6 (9.8%) at systemic sites, while in the CCRT/CT group, 9 patients (16.4%) relapsed at the primary site and 14 (25.5%) at systemic sites. The 5-year cumulative incidence of relapse (CIR) at primary sites was 26.3% and 19.2% after SCRT and CCRT/CT (p = 0.308), while the 5-year CIR of systemic sites was 8.7% and 26.5% after SCRT and CCRT/CT, respectively (p = 0.010). In the multivariate analysis, NK/T-cell Prognostic Index score and CR achievement were the most important prognostic factors for survival. Although up-front RT had limitations in systemic disease control and was associated with an increased risk of systemic relapse during RT compared to SCRT, timing of RT did not significantly affect survival outcomes.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalLeukemia Research
Volume49
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

T-Cell Lymphoma
Natural Killer Cells
Radiotherapy
Drug Therapy
Therapeutics
Recurrence
Extranodal NK-T-Cell Lymphoma
Survival
Incidence
Chemoradiotherapy
Multivariate Analysis
Survival Rate

Keywords

  • Chemotherapy
  • Extranodal NK/T cell lymphoma
  • Radiotherapy
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. / Moon, Joon Ho; Lee, Bo Hee; Kim, Jeong A.; Lee, Yoo Jin; Chae, Yee Soo; Yhim, Ho Young; Kwak, Jae Yong; Do, Young Rok; Park, Yong; Song, Moo Kon; Shin, Ho Jin; Kim, Therasa; Lee, Je jung; Yang, Deok Hwan.

In: Leukemia Research, Vol. 49, 01.10.2016, p. 80-87.

Research output: Contribution to journalArticle

Moon, JH, Lee, BH, Kim, JA, Lee, YJ, Chae, YS, Yhim, HY, Kwak, JY, Do, YR, Park, Y, Song, MK, Shin, HJ, Kim, T, Lee, JJ & Yang, DH 2016, 'Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma', Leukemia Research, vol. 49, pp. 80-87. https://doi.org/10.1016/j.leukres.2016.08.015
Moon, Joon Ho ; Lee, Bo Hee ; Kim, Jeong A. ; Lee, Yoo Jin ; Chae, Yee Soo ; Yhim, Ho Young ; Kwak, Jae Yong ; Do, Young Rok ; Park, Yong ; Song, Moo Kon ; Shin, Ho Jin ; Kim, Therasa ; Lee, Je jung ; Yang, Deok Hwan. / Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma. In: Leukemia Research. 2016 ; Vol. 49. pp. 80-87.
@article{7c7a09d536024da2bef09e1c98595d05,
title = "Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma",
abstract = "This study retrospectively investigated the optimal timing of radiotherapy (RT) in patients with limited-stage extranodal NK/T-cell lymphoma (ENTKL). Among 158 patients with newly diagnosed stage I/II ENKTL, 61 patients were treated with sequential chemotherapy followed by radiotherapy (SCRT), 55 with concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy (CCRT/CT), and 42 with chemotherapy (CT) only. The 5-year overall survival (OS) rate did not differ between SCRT (77.7 ± 5.5{\%}) and CCRT/CT (68.9 ± 6.8{\%}; p = 0.234). In the SCRT group, 18 patients (29.5{\%}) relapsed within the RT field and 6 (9.8{\%}) at systemic sites, while in the CCRT/CT group, 9 patients (16.4{\%}) relapsed at the primary site and 14 (25.5{\%}) at systemic sites. The 5-year cumulative incidence of relapse (CIR) at primary sites was 26.3{\%} and 19.2{\%} after SCRT and CCRT/CT (p = 0.308), while the 5-year CIR of systemic sites was 8.7{\%} and 26.5{\%} after SCRT and CCRT/CT, respectively (p = 0.010). In the multivariate analysis, NK/T-cell Prognostic Index score and CR achievement were the most important prognostic factors for survival. Although up-front RT had limitations in systemic disease control and was associated with an increased risk of systemic relapse during RT compared to SCRT, timing of RT did not significantly affect survival outcomes.",
keywords = "Chemotherapy, Extranodal NK/T cell lymphoma, Radiotherapy, Relapse",
author = "Moon, {Joon Ho} and Lee, {Bo Hee} and Kim, {Jeong A.} and Lee, {Yoo Jin} and Chae, {Yee Soo} and Yhim, {Ho Young} and Kwak, {Jae Yong} and Do, {Young Rok} and Yong Park and Song, {Moo Kon} and Shin, {Ho Jin} and Therasa Kim and Lee, {Je jung} and Yang, {Deok Hwan}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.leukres.2016.08.015",
language = "English",
volume = "49",
pages = "80--87",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Clinical impact of induction treatment modalities and optimal timing of radiotherapy for the treatment of limited-stage NK/T cell lymphoma

AU - Moon, Joon Ho

AU - Lee, Bo Hee

AU - Kim, Jeong A.

AU - Lee, Yoo Jin

AU - Chae, Yee Soo

AU - Yhim, Ho Young

AU - Kwak, Jae Yong

AU - Do, Young Rok

AU - Park, Yong

AU - Song, Moo Kon

AU - Shin, Ho Jin

AU - Kim, Therasa

AU - Lee, Je jung

AU - Yang, Deok Hwan

PY - 2016/10/1

Y1 - 2016/10/1

N2 - This study retrospectively investigated the optimal timing of radiotherapy (RT) in patients with limited-stage extranodal NK/T-cell lymphoma (ENTKL). Among 158 patients with newly diagnosed stage I/II ENKTL, 61 patients were treated with sequential chemotherapy followed by radiotherapy (SCRT), 55 with concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy (CCRT/CT), and 42 with chemotherapy (CT) only. The 5-year overall survival (OS) rate did not differ between SCRT (77.7 ± 5.5%) and CCRT/CT (68.9 ± 6.8%; p = 0.234). In the SCRT group, 18 patients (29.5%) relapsed within the RT field and 6 (9.8%) at systemic sites, while in the CCRT/CT group, 9 patients (16.4%) relapsed at the primary site and 14 (25.5%) at systemic sites. The 5-year cumulative incidence of relapse (CIR) at primary sites was 26.3% and 19.2% after SCRT and CCRT/CT (p = 0.308), while the 5-year CIR of systemic sites was 8.7% and 26.5% after SCRT and CCRT/CT, respectively (p = 0.010). In the multivariate analysis, NK/T-cell Prognostic Index score and CR achievement were the most important prognostic factors for survival. Although up-front RT had limitations in systemic disease control and was associated with an increased risk of systemic relapse during RT compared to SCRT, timing of RT did not significantly affect survival outcomes.

AB - This study retrospectively investigated the optimal timing of radiotherapy (RT) in patients with limited-stage extranodal NK/T-cell lymphoma (ENTKL). Among 158 patients with newly diagnosed stage I/II ENKTL, 61 patients were treated with sequential chemotherapy followed by radiotherapy (SCRT), 55 with concurrent chemoradiotherapy followed by non-anthracycline-based chemotherapy (CCRT/CT), and 42 with chemotherapy (CT) only. The 5-year overall survival (OS) rate did not differ between SCRT (77.7 ± 5.5%) and CCRT/CT (68.9 ± 6.8%; p = 0.234). In the SCRT group, 18 patients (29.5%) relapsed within the RT field and 6 (9.8%) at systemic sites, while in the CCRT/CT group, 9 patients (16.4%) relapsed at the primary site and 14 (25.5%) at systemic sites. The 5-year cumulative incidence of relapse (CIR) at primary sites was 26.3% and 19.2% after SCRT and CCRT/CT (p = 0.308), while the 5-year CIR of systemic sites was 8.7% and 26.5% after SCRT and CCRT/CT, respectively (p = 0.010). In the multivariate analysis, NK/T-cell Prognostic Index score and CR achievement were the most important prognostic factors for survival. Although up-front RT had limitations in systemic disease control and was associated with an increased risk of systemic relapse during RT compared to SCRT, timing of RT did not significantly affect survival outcomes.

KW - Chemotherapy

KW - Extranodal NK/T cell lymphoma

KW - Radiotherapy

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84984876293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984876293&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.08.015

DO - 10.1016/j.leukres.2016.08.015

M3 - Article

C2 - 27608179

AN - SCOPUS:84984876293

VL - 49

SP - 80

EP - 87

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -